John Hynes

John joined Kojin Therapeutics in May of 2021 as the Head of R&D. John will be responsible for driving the direction of the company’s chemistry effort as it relates to modulating ferroptosis via small molecules. John comes to Kojin after a 22-year career in medicinal chemistry at Bristol Myers Squibb where he was responsible for leading chemistry efforts from hit generation through clinical candidate nomination for various targets. His teams, both in the US and internationally, provided multiple clinical assets against key targets in the pipeline, specifically CCR1 and IRAK4. Prior to BMS, John was a National Institutes of Health post-doctoral fellow at the University of California at Irvine. John received his doctorate in organic chemistry from the University of Pennsylvania and his bachelor’s of chemistry from Eastern University. John is a co-author on 48 peer-reviewed publications and is a co-inventor on 49 issued patents and published patent applications.